BioSpace News Archive

Policy

Elizabeth Holmes Trial Could be Delayed Until 2021 Due to COVID-19 Surge

The trial was initially scheduled for July, but in April had been postponed until October due to the pandemic. A final decision will be made in August.

July 21, 2020
·
2 min read
·
Alex Keown
Policy

Biopharma Update on the Novel Coronavirus: July 22

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 22, 2020.

July 21, 2020
·
6 min read
·
BioSpace Editorial Staff
Business

Women in Bio: Rebecca Vaught Launches Van Heron Labs

Rebecca Vaught never set out to become an entrepreneur, but that’s exactly what happened when she launched Van Heron Labs earlier this year with a goal of reframing the understanding of the body’s organismal and cellular performance.

July 21, 2020
·
3 min read
·
Alex Keown
Business

House Subcommittee Hears from COVID-19 Vaccine Developers on Efficacy, Price and Availability

In an ongoing online hearing before the House Committee on Energy and Commerce’s Oversight and Investigation subcommittee, executives from across the pharmaceutical industry outlined the steps their companies are taking to combat COVID-19 and restore the world to a sense of normalcy.

July 21, 2020
·
4 min read
·
Alex Keown
Career Advice

How to Quantify Achievements on Your Resume

If you’re struggling to figure out how, exactly, to back up your accomplishments with facts, think about your impact, and then ask yourself some of these questions.

July 21, 2020
·
2 min read
·
Laura Brothers
BioMidwest

Forge Biologics Launches with $40 Million to Manufacture and Develop Gene Therapies

Forge Biologics is a viral vector contract development manufacturing organization (CDMO) and therapeutics developer.

July 21, 2020
·
2 min read
·
Alex Keown
Drug Development

Acadia’s Nuplazid Shows Mixed Results in Major Depression Study

ACADIA Pharmaceuticals reported topline data from its Phase III CLARITY study of Nuplazid (pimavanserin) as an adjunctive treatment for major depressive disorder (MDD).

July 21, 2020
·
2 min read
·
Mark Terry
Drug Development

CanSino’s Early Phase II COVID-19 Vaccine Data Shows Promise

CanSino Biologics, along with China’s military research unit, reported early data on its Phase II trial for its COVID-19 vaccine, Ad5-nCOV.

July 21, 2020
·
3 min read
·
Mark Terry
Business

Oxford Cautious About Timeline Following COVID-19 Vaccine Data

Oxford University, which by many standards is ahead of everyone in the vaccine development world, is suggesting end of the year is possible, but being very cautious about it.

July 21, 2020
·
3 min read
·
Mark Terry
Business

Elevation Oncology Launches with $32.5M in Series A Financing

In addition, the Phase II CRESTONE study has begun, examining the efficacy and safety of seribantumab in patients with solid tumors that feature a neuregulin-1 (NRG1) fusion.

July 21, 2020
·
3 min read
·
Krystle Vermes